The thesis
PanicFade v4 runs on a well-worn but defensible idea: markets overreact to bad news, and oversold quality names tend to revert toward fundamentals. The entry rule is specific — sentiment below -0.4 on a name that is also technically oversold (RSI14 under 35 and trading below its SMA20) — and the strategy sizes into the weakness rather than waiting for confirmation. Exits are symmetric: take reversion when RSI14 crosses 50 or price reclaims the SMA20, and hard-stop fresh lows on continued negativity, treating that as a genuine fundamental break rather than noise.
The universe is deliberately conservative: 24 mega- and large-cap US names across tech, financials, healthcare, staples, and industrials. Fading panic in liquid blue chips is a far safer expression of this edge than doing it in small caps, where "oversold" and "going to zero" look identical for too long. The approach cites recent sentiment-feedback research (arXiv:2509.11970 and corroborating 2025 work), which is more than most retail contrarian systems bother with.
Recent activity
The live book is lightly deployed: on 2026-11-11 it sat at a total of $9,746.28 with $5,661.17 in cash — roughly 40% invested. Activity has been steady but low-conviction: one or two executions per daily run, zero rejections.
The trade tape tells a more cautionary story. CAT has been churned repeatedly — bought at 621.97 (Nov 3), sold at 585.79, re-bought at 561.74, sold at 559.24, then bought again at 597.56 — a sequence of whipsaw round-trips. NVDA shows the fade catching a falling knife: bought at 204.04 (Nov 2), sold at 177.08 (Nov 9), then re-entered lower at 166.95 (Nov 10). These are exactly the scenarios the thesis anticipates, but they are also where mean-reversion bleeds.
Validation and backtest
The out-of-sample work is the strongest part of the file. Validation passed with 4 of 4 folds positive, OOS return of 21.7% and an OOS Sharpe of 2.44 in the most recent fold. The Probabilistic Sharpe Ratio of 0.985 is excellent; the Deflated Sharpe of 0.56, adjusted for 27 trials, is the honest number — respectable, not spectacular. Fold returns climb monotonically (1.6% → 3.88% → 10.14% → 21.7%), which could reflect a favorable recent regime as easily as a durable edge.
Headline backtest numbers: 37.93% total return over 1,233 days (a 6.79% CAGR), Sharpe 0.96, max drawdown 9.3%, and a 62.88% win rate across 530 trades.
Strengths and risks
The strengths are real: a literature-grounded thesis, clean multi-fold validation, controlled drawdown, and a liquid universe. The risks are equally plain. Turnover of 5,807% is enormous — this is a high-churn strategy whose edge is easily eaten by costs and slippage. The ~0.96 Sharpe and single-digit CAGR mean the backtest reward is modest for the activity involved, and the live book is currently flat-to-down rather than confirming the research. Worth watching, not yet worth conviction.